RxDoctor Payments Data

John Burkett, MD

Neurology · Pittsburgh, PANPI 1205255809

Payments from drug & device makers

$19,163in general payments, 2019–2025

Across 116 payments — averaging $165.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$17K
  • Lundbeck LLC$767
  • Lilly USA, LLC$254
  • Teva Pharmaceuticals USA, Inc.$203
  • Novartis$124
  • Amgen$93
  • plus $271 from 5 others

What the payments were for

  • Speaking & faculty fees$15,75082%
  • Travel & lodging$20%
  • Food & beverage$3,41018%
  • Education$10%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,163 in reported general payments places this provider in the 75th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$18,097
Medicare patients
130
Services billed
246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant190$282,191
Emgality PenGalcanezumab-Gnlm199$145,519
Nurtec OdtRimegepant Sulfate76$109,605
QuliptaAtogepant65$69,048
Emgality SyringeGalcanezumab-Gnlm80$59,669
Ajovy AutoinjectorFremanezumab-Vfrm45$31,509
Aimovig AutoinjectorErenumab-Aooe34$29,294
Topiramate155$1,905
Gabapentin160$1,810
Carbamazepine ErCarbamazepine18$1,418
Carbamazepine18$1,052
Nortriptyline Hcl62$1,025
Naratriptan Hcl33$988
Eletriptan HbrEletriptan Hydrobromide14$931
Frovatriptan Succinate11$842

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$17,450$351,239255 claims
PfizerNurtec Odt$90$109,60576 claims
Dr.reddy's Laboratories,inc.Pregabalin, Lamotrigine, Divalproex Sodium$27$50457 claims
Lilly USA, LLCOlanzapine$254$5319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →